Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression
Public ClinicalTrials.gov record NCT04400058. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Efficacy and Safety of Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a randomized, double-blind, placebo-controlled, multicenter, Phase 3 study to evaluate if high-dose Octagam 10% therapy can stabilize or improve clinical status in patients with severe Coronavirus disease
Study identification
- NCT ID
- NCT04400058
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 207 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2020
- Primary completion
- Jan 31, 2022
- Completion
- Jan 31, 2022
- Last update posted
- Jan 17, 2024
2020 – 2022
United States locations
- U.S. sites
- 15
- U.S. states
- 11
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Octapharma Research Site | Sheffield | Alabama | 35660 | — |
| Octapharma Research Site | Loma Linda | California | 92354 | — |
| Octapharma Research Site | Loma Linda | California | 92357 | — |
| Octapharma Research Site | Newport Beach | California | 92663 | — |
| Octapharma Research Site | Orange | California | 92868 | — |
| Octapharma Research Site | San Diego | California | 92123 | — |
| Octapharma Research Site | Washington D.C. | District of Columbia | 20007 | — |
| Octapharma Research Site | Honolulu | Hawaii | 96813 | — |
| Octapharma Research Site | Iowa City | Iowa | 52242 | — |
| Octapharma Research Site | Covington | Louisiana | 70433 | — |
| Octapharma Research Site | Midland | Michigan | 48670 | — |
| Octapharma Research Site | Las Vegas | Nevada | 89102 | — |
| Octapharma Research Site | Minot | North Dakota | 58701 | — |
| Octapharma Research Site | Charleston | South Carolina | 29401 | — |
| Octapharma Research Site | Tyler | Texas | 75708 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04400058, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 17, 2024 · Synced Sep 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04400058 live on ClinicalTrials.gov.